Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06903273 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma

Study acronym: TisGCS for BTC
StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
To investigate the efficacy and tolerability of neoadjuvant tislelizumab, gemcitabine, cisplatin and S-1 (TisGCS) in patients with resectable high-risk iCCA.
Trial Details
NCT Number NCT06903273
Lead Sponsor National Cheng-Kung University Hospital
Collaborators: Kaohsiung Veterans General Hospital., Chi Mei Medical Hospital
Conditions
(from sponsor)		 Cholangiocarcinoma, Biliary Tract Cancer (BTC)
Related terms Biliary Tract Neoplasms, Cholangiocarcinoma
Enrollment 35 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov